First Capital Advisors Group’s Amphastar Pharmaceuticals AMPH Stock Holding History

First Capital Advisors Group’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$2.41K	Buy	+42	New	+$1.86K	﹤0.01%	788

Other funds holding AMPH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Capital Advisors Group's AMPH Position: Q2 2023 in Review

First Capital Advisors Group opened a new position in Amphastar Pharmaceuticals (AMPH) in Q2 2023: 42 shares worth $2.41K. The stake represents ﹤0.01% of the portfolio and ranks #788 among its holdings.

246 funds tracked by Wall St. Rank hold AMPH as of Q2 2023.

First Capital Advisors Group held 42 shares of Amphastar Pharmaceuticals worth $2.41K as of Q2 2023.
Amphastar Pharmaceuticals was a new First Capital Advisors Group position in Q2 2023.
Amphastar Pharmaceuticals made up ﹤0.01% of First Capital Advisors Group's portfolio in Q2 2023, its #788 holding.
246 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2023.

Based on First Capital Advisors Group's 13F filing for Q2 2023, filed 15 Aug 2023.